Clinical trial
Rituximab as Second Line Treatment for ITP
NCT00344149 · Ostfold Hospital Trust, Other · Completed
Key facts
| NCT number | NCT00344149 |
|---|---|
| Title | Rituximab as Second Line Treatment for ITP |
| Official title | Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" |
| Lead sponsor | Ostfold Hospital Trust, Other |
| Collaborators | Oslo University Hospital South-Eastern Regional Health Authority |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Immune Thrombocytopenia (ITP) |
| Intervention type | Drug |
| Interventions | Rituximab (Mabthera) |
| Enrollment | 112 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2014 |
| First posted | Jun 26, 2006 |
| Last update posted | Mar 26, 2014 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: